Olympus Corporation
7733.T
Below: live stock price for Olympus Corporation (7733.T), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Olympus Corporation (7733.T) is a Healthcare company based in Japan. Operating in Medical Devices, it employs about 28,138 people. Over the past year 7733.T traded between 1,302.5 and 2,210.5 JPY. Trailing P/E sits near 28.46 on a market cap of about 1.85T JPY. It currently yields 1.72% in dividends.
- Prev close
- $11.23
- Volume (24h)
- $54.36M
- Market cap
- $11.76B
- Currency
- USD (native JPY)
Score
48/ 100 · Mixed
- Value36
- Quality58
- Momentum28
- Growth76
- Risk65
- Dividend47
- Liquidity25
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 10.9421 -1.07%
- +20 bars
- 10.7805 -2.53%
- +60 bars
- 10.7187 -3.09%
- +120 bars
- 10.7164 -3.11%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: 1σ ≈ ±2.75% per bar.
Interpretation
Composite signals look mixed. Strength: growth with weakness: balance-sheet liquidity. Price sits near the lower third of the recent range, trend is sloping downward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value36/100
Value looks weak — driven by P/E (28.46).
P/E:28.46P/B:2.48PEG:3.61 - Quality58/100
Quality looks mixed — driven by Gross margin (64.70%).
ROE:10.57%ROA:6.33%Profit margin:7.49%Gross margin:64.70% - Momentum28/100
Momentum looks fragile — driven by 52w change (-8.12%).
52w change:-8.12% - Growth76/100
Growth looks strong — driven by Earnings growth (122.60%).
Revenue growth:16.40%Earnings growth:122.60% - Risk65/100
Risk looks solid — driven by Debt / equity (42.64).
Beta:0.26Debt / equity:42.64 - Dividend47/100
Dividend looks mixed — driven by Payout ratio (49.02%).
Dividend yield:1.72%Payout ratio:49.02% - Liquidity25/100
Liquidity looks fragile — driven by Current ratio (1.36).
Current ratio:1.36Quick ratio:0.72
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 243 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 44.3%
- Max drawdown
- -38.1%
- Below period high
- -21.2%
- Best day
- +19.83%
- Worst day
- -13.46%
- Up days
- 43%
- Current streak
- 1 down
- Typical day swing
- 2.5%
- Volume vs average
- +18%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 14.0354 high → 10.594 low · 60 bars
- ResistanceFib +161.8% extensionnot reached19.6036 USD+77.24% from current
- ResistanceFib +100% extensionnot reached17.4768 USD+58.01% from current
- ResistanceFib +61.8% extensionnot reached16.1622 USD+46.12% from current
- ResistanceFib +27.2% extensionnot reached14.9715 USD+35.36% from current
- ResistanceFib 23.6% retracementtested 7×13.2233 USD+19.55% from current
- ResistanceFib 38.2% retracementtested 16×12.7208 USD+15.01% from current
- ResistanceFib 50% midpointtested 2×12.3147 USD+11.34% from current
- ResistanceFib 61.8% retracementtested 1×11.9086 USD+7.67% from current
- ResistanceFib 78.6% retracementNearesttested 2×11.3305 USD+2.44% from current
- Current11.0607 USD
- SupportFib −27.2% extensionnot reached9.658 USD-12.68% from current
- SupportFib −61.8% extensionnot reached8.4672 USD-23.45% from current
- SupportFib −100% extensionnot reached7.1526 USD-35.33% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- ¥2,210.5
- 52w low
- ¥1,302.5
- 52w change
- -8.12%
- Day high
- ¥1,785.5
- Day low
- ¥1,741.5
- P/E (TTM)
- 28.46
- Forward P/E
- 13.87
- PEG
- 3.61
- Price / Book
- 2.48
- Beta (5Y)
- 0.26
- Enterprise value
- 2.05T
- EV / Revenue
- 1.96
- EV / EBITDA
- 9.38
- EPS (TTM)
- ¥61.2
- Forward EPS
- ¥125.64
- Dividend yield
- 1.72%
- Dividend rate
- ¥30
- Payout ratio
- 49.02%
- Revenue (TTM)
- 1.04T
- EBITDA
- 218.71B
- Free cash flow
- 17.3B
- Total cash
- 118.54B
- Total debt
- 318.89B
- Debt / Equity
- 42.64
- Current ratio
- 1.36
- Quick ratio
- 0.72
- Profit margin
- 7.49%
- Gross margin
- 64.70%
- Return on assets
- 6.33%
- Return on equity
- 10.57%
- Shares outstanding
- 1.06B
- Float
- 1.06B
Olympus Corporation, together with its subsidiaries, engages in the manufacture and sale of medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through two segments, Gastrointestinal Solutions and Surgical & Interventional Solutions. The company offers gastrointestinal Solutions products offer gastrointestinal endoscopes, gastroenterology devices, and medical services. The Surgical & Interventional Solutions provides urology, respiratory, surgical endoscopes, energy devices, ENT products, and gynecology products. It also provides respiratory products comprising bronchoscopy systems and devices, lung cancer products, and chronic obstructive pulmonary disease products; urology products consisting of visualization, stone management, benign prostatic hyperplasia (BPH), and BPH + bladder cancer products; surgical products, such as surgical endoscopy systems, advanced energy devices, surgical microscope, integrated procedure room solutions, and rhino-laryngoscopy systems, as well as surgical devices for the ears, nose, and throat. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Hachioji, Japan.
Analyst & Risk
Analysts' consensus via Yahoo Finance — not investment advice.
- Beta (vs S&P 500)
- 0.26
- very stable
- 52-week change
- -8.12%
- Debt / Equity
- 42.64
- very high leverage
- Current ratio
- 1.36
- Quick ratio
- 0.72
- ROE
- 10.57%
- ROA
- 6.33%
- PEG ratio
- 3.61
- EV / Revenue
- 1.96
- EV / EBITDA
- 9.38
- Revenue growth
- 16.40%
- Earnings growth
- 122.60%
- EBITDA
- 218.71B
- Free cash flow
- 17.3B
- Total cash
- 118.54B
- Total debt
- 318.89B
- Insider holdings
- 4.22%
- Institutional
- 61.70%
Related
Other assets in this category.
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.